These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 24173008

  • 1. A review of tuberculosis: Focus on bedaquiline.
    Chan B, Khadem TM, Brown J.
    Am J Health Syst Pharm; 2013 Nov 15; 70(22):1984-94. PubMed ID: 24173008
    [Abstract] [Full Text] [Related]

  • 2. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV, Estrada SJ.
    Pharmacotherapy; 2014 Nov 15; 34(11):1187-97. PubMed ID: 25203970
    [Abstract] [Full Text] [Related]

  • 3. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 2013 Oct 25; 62(RR-09):1-12. PubMed ID: 24157696
    [Abstract] [Full Text] [Related]

  • 4. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
    Chahine EB, Karaoui LR, Mansour H.
    Ann Pharmacother; 2014 Jan 25; 48(1):107-15. PubMed ID: 24259600
    [Abstract] [Full Text] [Related]

  • 5. Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.
    Nguyen TV, Cao TB, Akkerman OW, Tiberi S, Vu DH, Alffenaar JW.
    Expert Rev Clin Pharmacol; 2016 Aug 25; 9(8):1025-37. PubMed ID: 27322153
    [Abstract] [Full Text] [Related]

  • 6. Bedaquiline: a novel antitubercular drug for multidrug-resistant tuberculosis.
    Nagabushan H, Roopadevi HS.
    J Postgrad Med; 2014 Aug 25; 60(3):300-2. PubMed ID: 25121373
    [Abstract] [Full Text] [Related]

  • 7. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
    Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, Khachatryan N, De Avezedo V, Egazaryan L, Shroufi A, Kalon S, Cox H, Furin J, Isaakidis P.
    Lancet Infect Dis; 2018 May 25; 18(5):536-544. PubMed ID: 29452942
    [Abstract] [Full Text] [Related]

  • 8. TMC207 becomes bedaquiline, a new anti-TB drug.
    Palomino JC, Martin A.
    Future Microbiol; 2013 Sep 25; 8(9):1071-80. PubMed ID: 24020736
    [Abstract] [Full Text] [Related]

  • 9. Bedaquiline: An Insight Into its Clinical Use in Multidrug-Resistant Pulmonary Tuberculosis.
    Ahmad A, Akhtar J, Ahmad M, Khan MI, Wasim R, Islam A, Singh A.
    Drug Res (Stuttg); 2024 Jul 25; 74(6):269-279. PubMed ID: 38968950
    [Abstract] [Full Text] [Related]

  • 10. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls.
    Kakkar AK, Dahiya N.
    Tuberculosis (Edinb); 2014 Jul 25; 94(4):357-62. PubMed ID: 24841672
    [Abstract] [Full Text] [Related]

  • 11. Bedaquiline for the treatment of pulmonary, multidrug-resistant tuberculosis in adults.
    Gras J.
    Drugs Today (Barc); 2013 Jun 25; 49(6):353-61. PubMed ID: 23807939
    [Abstract] [Full Text] [Related]

  • 12. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
    Achar J, Hewison C, Cavalheiro AP, Skrahina A, Cajazeiro J, Nargiza P, Herboczek K, Rajabov AS, Hughes J, Ferlazzo G, Seddon JA, du Cros P.
    Emerg Infect Dis; 2017 Oct 25; 23(10):1711-3. PubMed ID: 28758889
    [Abstract] [Full Text] [Related]

  • 13. Multidrug-resistant tuberculosis and culture conversion with bedaquiline.
    Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B, TMC207-C208 Study Group.
    N Engl J Med; 2014 Aug 21; 371(8):723-32. PubMed ID: 25140958
    [Abstract] [Full Text] [Related]

  • 14. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.
    Kunkel A, Cobelens FG, Cohen T.
    PLoS Med; 2016 Oct 21; 13(10):e1002142. PubMed ID: 27727274
    [Abstract] [Full Text] [Related]

  • 15. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study.
    Gao M, Gao J, Xie L, Wu G, Chen W, Chen Y, Pei Y, Li G, Liu Y, Shu W, Fan L, Wu Q, Du J, Chen X, Tang P, Xiong Y, Li M, Cai Q, Jin L, Mei Z, Pang Y, Li L.
    Clin Microbiol Infect; 2021 Apr 21; 27(4):597-602. PubMed ID: 32553880
    [Abstract] [Full Text] [Related]

  • 16. Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens.
    Riccardi N, Del Puente F, Magnè F, Taramasso L, Di Biagio A.
    Recent Pat Antiinfect Drug Discov; 2018 Apr 21; 13(1):3-11. PubMed ID: 28625141
    [Abstract] [Full Text] [Related]

  • 17. Bedaquiline versus placebo for management of multiple drug-resistant tuberculosis: A systematic review.
    Charan J, Reljic T, Kumar A.
    Indian J Pharmacol; 2016 Apr 21; 48(2):186-91. PubMed ID: 27127322
    [Abstract] [Full Text] [Related]

  • 18. ▼Bedaquiline for multidrug-resistant tuberculosis.
    Drug Ther Bull; 2014 Nov 21; 52(11):129-32. PubMed ID: 25395481
    [Abstract] [Full Text] [Related]

  • 19. Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety.
    Gao JT, Du J, Wu GH, Pei Y, Gao MQ, Martinez L, Fan L, Chen W, Xie L, Chen Y, Wang H, Jin L, Li GB, Zong PL, Xiong Y, Wu QH, Li MW, Yan XF, Miao YF, Cai QS, Li XJ, Bai DP, Geng SJ, Yang GL, Tang PJ, Zeng Y, Chen XH, Li TX, Cai C, Zhou Y, Zhuo M, Wang JY, Guan WL, Xu L, Shi JC, Shu W, Cheng LL, Teng F, Ning YJ, Xie SH, Sun YX, Zhang LJ, Liu YH.
    Infect Dis Poverty; 2021 Mar 19; 10(1):32. PubMed ID: 33736710
    [Abstract] [Full Text] [Related]

  • 20. Bedaquiline.
    Goulooze SC, Cohen AF, Rissmann R.
    Br J Clin Pharmacol; 2015 Aug 19; 80(2):182-4. PubMed ID: 25702772
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.